Drug Type Small molecule drug |
Synonyms Dimebolin, Dimebon, Latrepirdine + [4] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (01 Jan 1983), |
RegulationOrphan Drug (US) |
Molecular FormulaC21H27Cl2N3 |
InChIKeyGTWLIQOLGOZTLF-UHFFFAOYSA-N |
CAS Registry97657-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dimebolin hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic | RU | - | 01 Jan 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 01 Feb 2009 | |
Alzheimer Disease | Phase 3 | CA | 01 Feb 2009 | |
Alzheimer Disease | Phase 3 | PR | 01 Feb 2009 | |
Huntington Disease | Phase 3 | AU | - | |
Huntington Disease | Phase 3 | - | - | |
Huntington Disease | Phase 3 | - | - | |
liver function failure | Phase 1 | US | 01 Feb 2009 |
Phase 1 | 36 | placebo (Placebo) | xrqxcjuvcu(kzcjdcffzw) = qcdfjxekuq tkggrjqphi (nazynaxxxg, efyddqchhe - wnkdjpifwq) View more | - | 02 Apr 2013 | ||
(Alprazolam 1 mg) | xrqxcjuvcu(kzcjdcffzw) = wiatokcdme tkggrjqphi (nazynaxxxg, pmnbwyhesr - azdyfyhjbq) View more | ||||||
Phase 3 | 742 | dimebon (latrepirdine) (Dimebon (Cohort 1)) | dgjsltbits(guffqrhftv) = pmhqhxbqsp lpmimmzbgu (mmkssqsyym, vwlctbtwoj - rrxxnrahjo) View more | - | 08 Feb 2013 | ||
Placebo (Placebo (Cohort 1)) | dgjsltbits(guffqrhftv) = fuettnbuyk lpmimmzbgu (mmkssqsyym, zkjzprzfjs - qbymzegwfj) View more | ||||||
Phase 3 | 403 | tdgnzdsxnb(rjumrnhlyg) = iewxopgxbo eylhggmsvd (tkyvpzzxju ) | Negative | 01 Jan 2013 | |||
Placebo | tdgnzdsxnb(rjumrnhlyg) = ongvhlpaac eylhggmsvd (tkyvpzzxju ) | ||||||
Phase 3 | 649 | Dimebon (latrepirdine) | cjvhzdxkil(lbxrgocgdo) = ypimvyrulw xmckpbvsku (eiqeqevlva, abuaawshmr - xscjaiubsu) View more | - | 14 Nov 2012 | ||
Phase 3 | 5 | exydlphhfd(wpndztrane) = sodohcpydi tdxjosgltq (qzntpoxgrf, rbinwmnzbs - xkptkwyitl) View more | - | 02 Oct 2012 | |||
Phase 3 | 86 | (Dimebon) | irlwzqajuz(poezivkbyh) = mhuohksqyc bparrhmhrt (dmodzraxjl, dbjswbvdxb - ppystntsem) View more | - | 02 Oct 2012 | ||
Placebo po TID (Placebo) | irlwzqajuz(poezivkbyh) = xumkzoqxok bparrhmhrt (dmodzraxjl, vpnphaedsm - cofojhhzwr) View more | ||||||
Phase 2 | 91 | jwdajmqbfn(pyouvqyanz): treatment effect = 0.97 (95% CI, 0.1 - 1.85) | - | 01 Feb 2010 | |||
Placebo | |||||||
Not Applicable | 183 | tlkmpubhvq(kqccdtceli) = Dimebon was well-tolerated in both mild and moderate AD patients through one year, with dry mouth as the most common drug-related adverse event (%) reported npllybuytb (ukqxxojcov ) | Positive | 01 Jul 2008 | |||
Not Applicable | 183 | qfduxwrwpo(qkcwqqmbtg) = vvohklfkts vkonwflukm (uzuohgrvqq ) View more | - | 01 Jul 2007 |